Malachite Innovations, Inc. (VBIO)

OTC Healthcare Biotechnology

Vitality Biopharma, Inc. specializes in creating cannabinoid-based pharmaceuticals, primarily focusing on addressing inflammatory disorders within the United States. Its current pipeline includes tetrahydrocannabinol glycoside, identified as VBX-100, an orally administered cannabinoid prodrug engineered to combat inflammatory bowel disease (IBD) and irritable bowel syndromes (IBS). Established in 2007, the company originally operated as Stevia First Corp. before officially rebranding as Vitality Biopharma, Inc. in July 2016. Its corporate headquarters are situated in Los Angeles, California.